MedTrace Logo

Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy Pilot Trial

NCT05172934 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-03-21

No results posted yet for this study

Summary

Prospective, single center, non-randomized, pilot study to assess the feasibility of IA TNK following standard of care mechanical thrombectomy (MT) in patients with AIS. Participants will receive IA TNK after achieving mTICI 2b or 2c reperfusion with standard of care MT. Patients enrolled into the study will be followed for 3 months after treatment with IA TNK.

Conditions

Interventions

DRUG

intra-arterial tenecteplase

intra-arterial drug administered after mechanical thrombectomy

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • ProMedica Health System

    lead OTHER

Principal Investigators

  • Syed F Zaidi, MD · ProMedica Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2023-09-12
Completion
2023-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172934 on ClinicalTrials.gov